Join Sandy Kotiah, MD, as she walks though the need for earlier intervention in GEP-NETs, an introduction to LUTATHERA, and the LUTATHERA mechanism of action.

Sandy Kotiah, MD, provides a brief review of the efficacy and safety of LUTATHERA in the NETTER-1 and NETTER-2 trials.

Sandy Kotiah, MD, shares her perspectives on which patients may be eligible for LUTATHERA therapy, insights on identifying progression in GEP-NETs, and resources for providers and patients.

GEP-NETs, gastroenteropancreatic neuroendocrine tumors.